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Abstract
Background: Acinetobacter baumannii is an increasingly multidrug-resistant (MDR) cause of hospital-acquired infections,
often associated with limited therapeutic options. We investigated A. baumannii isolates at a New York hospital to
characterize genetic relatedness.
Methods: Thirty A. baumannii isolates from geographically-dispersed nursing units within the hospital were studied. Isolate
relatedness was assessed by repetitive sequence polymerase chain reaction (rep-PCR). The presence and characteristics of
integrons were assessed by PCR. Metabolomic profiles of a subset of a prevalent strain isolates and sporadic isolates were
characterized and compared.
Results: We detected a hospital-wide group of closely related carbapenem resistant MDR A. baumannii isolates. Compared
with sporadic isolates, the prevalent strain isolates were more likely to be MDR (p=0.001). Isolates from the prevalent strain
carried a novel Class I integron sequence. Metabolomic profiles of selected prevalent strain isolates and sporadic isolates
were similar.
Conclusion: The A. baumannii population at our hospital represents a prevalent strain of related MDR isolates that contain a
novel integron cassette. Prevalent strain and sporadic isolates did not segregate by metabolomic profiles. Further study of
environmental, host, and bacterial factors associated with the persistence of prevalent endemic A. baumannii strains is
needed to develop effective prevention strategies.
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Introduction
Acinetobacter baumannii is a nonfermentative, nonmotile, oxidase-
negative, catalase positive gram-negative bacillus [1], and is an
increasing cause of intensive care unit and hospital-associated
infections [2]. Though the attributable mortality of A. baumannii
infection continues to be debated [1], clinicians increasingly are
confronted with infections with few or no antibiotic options. For
this reason, A. baumannii has been identified as a particularly
problematic pathogen by the Antimicrobial Availability Task
Force of the Infectious Disease Society of America [3].
A. baumannii is now prevalent throughout New York City
hospitals [4]. Like most hospitals in the area, NewYork-
Presbyterian Hospital/Weill Cornell Medical College (NYPH/
WCMC) has experienced an increase in A. baumannii infection and
colonization during the last 10 years, though the relatedness of the
isolates was largely unknown. We therefore studied the genetic
relatedness of the hospital wide A. baumannii population at NYPH/
WCMC during a period when the incidence and prevalence were
stable. We subsequently compared the microbiologic, genetic, and




Institutional Review Board approval with waiver of informed
consent was obtained. Isolates cultured at least 48 hours after
admission between February and December 2008 were prospec-
tively obtained from the Clinical Microbiology Laboratory, as
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ity testing. VITEK2 GN13 cards (bioMe ´rieux Inc., Durham, NC)
were used to identify members of the A. calcoaceticus-A. baumannii
complex, and to assess antimicrobial susceptibility. In addition,
Etests (AB bioMe ´rieux, Durham, NC) were used to assess
susceptibility to polymyxin B and tigecycline when requested by
treating clinicians, or when the isolate was multidrug resistant.
Multidrug-resistance (MDR) was defined as susceptibility to #1
tested antibiotic, excluding tigecycline and polymyxin B. No
additional antimicrobial resistance testing was performed beyond
what had been done for clinical purposes. Nursing unit and date of
culture were obtained from the electronic medical record.
Available A. baumannii isolates were intermittently collected from
the microbiology laboratory during the study period. A total of
103 A. baumannii isolates from 50 patients were available, and only
the first isolate per patient was used for this study. The total
number of patients with an A. baumannii culture during the study
period was 128. Isolates from 78 patients were unavailable due to
sporadic collection of isolates. A convenience sample of 30 study
isolates was selected from among the collected isolates to represent
the largest number of intensive care units (ICUs) and wards in
order to characterize the hospital wide A. baumannii population.
The 19 excluded first isolates were from ICU patients whose ICU
was already represented in the study database (12), non-ICU
patients with contaminated plates (3), and from patients in hospital
for less than 48 hours at the time of collection (4). The 12 excluded
ICU isolates all contained the same integron pattern as the
prevalent endemic isolates identified in the study. One of the 4
isolates collected in the first 48 hours was included (WC-31) since
they had been transferred from an outside hospital and thus
provided an opportunity to compare hospital strains. Only one
isolate per patient was studied.
Characterization of Isolates
All study isolates underwent Repetitive PCR (Rep-PCR) testing
and Class I Integron analysis. After the initial analysis showed a
prevalent endemic group of related isolates and additional sporadic
isolates, we made the simplifying assumption that isolates with
closely linked Rep-PCR results were of the same species and Multi
Locus Sequence Typing (MLST) type. Thus, OXA-51-like gene
amplification was done on all sporadic and the closest 5 prevalent
endemic isolates, and MLST typing was done on a single prevalent
endemic isolate. Metabolome analysis was performed on a subset of
prevalent and endemic isolates. DNA templates and primers were
prepared as described by Levasque et al. [5] with the exception that
3–5 colonies were dissolved in 100 ml of nuclease- free water, and
selectiveantibiotics were notused. PCRamplification conditionsfor
the 59CS -39CS integron analysis were as described by Martinez-
Freijo et al. [6], with a two minute annealing time. A second PCR
with non-overlapping primers was used to verify the integron
contents of the prevalent endemic strain [7]. A. baumannii, OXA-51-
like chromosomal genes were amplified from isolates WC 1–12
using previously described primers [8]. High Fidelity PCR Master
mix was used for all reactions (Roche, Indianapolis, IN). PCR
product nucleotide sequences were determined by Macrogen USA
(Rockville, MD). Sequences were compared to known sequences
using the Basic Local Alignment Search Tool (BLAST). MLST was
performed using a selected isolate from the prevalent endemic strain
and compared to the Pasteur MLST site (http://www.pasteur.fr/
recherche/genopole/PF8/mlst/Abaumannii.html).
Repetitive-PCR typing
DNA was extracted using the UltraClean
TM microbial DNA
isolation kit (MO BIO Labs, Inc., Solana Beach, CA). Rep-PCR
was performed using the DiversiLab system (bioMe ´rieux Inc.,
Durham, NC). The model 2100 bioanalyzer and LabChip
reagents (Agilent Technologies Inc., Palo Alto, CA) were used
for DNA separation. The DiversiLab system created dendro-
grams, scatterplots, electropherograms, and virtual gel images
for data analysis. Similarity criteria were followed as per Saeed
[9].
Metabolome Analysis
Differences in the metabolic properties of selected isolates were
studied by examining individual metabolites of interest and global
metabolic profiles. Biological replicates of A. baumannii isolates
were cultivated in phosphate-M9 minimal media [10] and grown
for metabolomic profiling on phosphate-M9 agar [11]. Bacterial
isolates were harvested during mid-logarithmic phase of growth,
and metabolites were isolated as described previously [12].
Variations in biomass were normalized for all isolates by analysis
of residual protein content [13]. An Agilent Accurate Mass 6220
time-of-flight mass spectrometer coupled to an Agilent 1200 liquid
chromatography system was used as described previously [12].
Data were collected in centroid mode in 2 GHz (extended
dynamic range) mode. Detected masses were deemed identified
metabolites on the basis of unique accurate mass retention times
which confirmed to the expected metabolites’ mass and that of
accompanying isotopomers [14]. Deconvolution of mass spectra
was performed using the Agilent MassHunter Qualitative Analysis
molecular feature extraction algorithm which identifies individual
metabolites using chromatographically covariant ion families
which conform to specific empirical formulae [14]. The normal-
ized ion counts (in triplicate) of 3 prevalent endemic strain isolates
were compared to the ion counts of 3 sporadic isolates (in
triplicate), and compared using Stata version 10.0 by Wilcoxon
Rank-Sum test. Additional statistical analyses used GeneSpring
MS software to perform principle components analysis (PCA) and
hierarchical clustering analysis (HCA).
Results
Study Isolates and Antimicrobial Susceptibility
Thirty isolates from unique patients were studied (Table 1).
The study isolates represented 24.2% of the 128 A. baumannii
isolates cultured from unique patients during that period. Patient
locations at the time of culture were geographically widespread,
including seven ICUs (5 floors) and seven non-ICU nursing units
(5 floors) over a 9 month period. An additional isolate (WC-31),
cultured on the first day of hospitalization from a patient
transferred to NYPH/WCMC from another hospital in Brooklyn
in New York City, was also included in the rep-PCR and integron
analyses.
The majority (70%) of the isolates in this study were multidrug-
resistant. The proportion of isolates susceptible to tested
antimicrobial agents included ampicillin-sulbactam (33%), imi-
penem or meropenem (23%), cefepime (17%), gentamicin (27%),
tobramycin (33%), amikacin (33%), trimethoprim-sulfamethoxa-
zole (17%), and levofloxacin (20%). In contrast, 20 of the 22
(91%) isolates tested were susceptible to polymyxin B
(MIC#2 mg/mL), though the MICs for eight were between 1.5
and 2 mg/mL. Tigecycline MICS were #2 mg/mL for 11 of the
25 (44%) isolates tested. The chromosomal A. baumannii gene bla-
OXA-51-like carbapenemase gene [8] could not be amplified
from four isolates (WC 1–4), suggesting that they belonged to
other A. calcoaceticus-A. baumannii complex species. Pending further
identification, these isolates are considered ‘‘A. baumannii’’ in this
study.
Endemic A. baumannii in a N.Y. Hospital
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Rep-PCR testing showed that 23 of 30 (77%) study isolates were
closely related with similarity scores over 90% (Figure 1). This
prevalent endemic strain of 23 isolates, hereafter referred to as the
‘‘prevalent strain’’, was geographically widespread and cultured
from patients in 7 ICUs and 6 non-ICU nursing units. The isolate
obtained from a patient transferred from a Brooklyn hospital (WC-
31), was highly similar to the prevalent strain. MLST of a one
prevalent strain isolate (WC-9) was consistent with ST-2, a
member of Worldwide Clone II [15].
Seven additional isolates were not closely related to the
prevalent group, or to each other, hereafter referred to as
‘‘sporadic isolates’’. One of the seven (14.3%) sporadic isolates
was MDR, compared with 20 of 23 (87%) prevalent strain isolates.
Prevalent strain isolates were thus more likely to be MDR than the
sporadic isolates (two tail Fisher’s Exact p=0.001).
Integron Assessment of Prevalent A. baumannii
Amplification of the integron variable region showed that all
prevalent strain isolates contained a common 550 base pair
product (GenBank # JF309278, Figure 2). In contrast, the
sporadic isolates contained products of varying sizes (data not
shown), though two also contained an identically sequenced 550
base pair product. BLAST sequence analysis of the 550 base pair
integron variable region showed 100% homology with a non-
integron-associated A. baumannii-associated sequence, which in-
cluded a portion of a glucose-sorbosone dehydrogenase encoding
gene (gb|CP000863.1). The same PCR sequence was amplified
Table 1. Study Isolates.
WC PT Date FLOOR A/S Carb Cef Gent Amik S/T LEVO PM Tig SOURCE
1 68F 9/5 A ICU S S S S S R S RESP
2 48M 2/29 A ICU R R R R R R I 0.8 4 RESP
3 12F 9/26 B ICU S S S S S S S RESP
4 18F 8/3 B ICU S S S S S S S 0.5 RESP
5 58M 10/8 C ICU S S I S R R I RESP
6 40F 7/30 B WARD S S S S S S S URINE
7 79F 8/24 D ICU S S S S S S S RESP
8 76M 9/22 E ICU S R R R R R R 1 12 RESP
9 76F 10/26 C ICU R R R R I R I 0.75 4 RESP
10 71M 11/7 D WARD R R R R R R R 1 12.5 BLOOD
11 3F 8/8 B ICU R R R R R R I 1.5 3 RESP
12 6M 9/15 A ICU R R R R S R I 1.5 3 URINE
13 78F 7/13 D WARD S R R R R S S 1 3 URINE
14 46F 6/24 D ICU R R R R R R R 4 2 BLOOD
15 67M 9/20 E ICU R R R R I R R 1 2 RESP
16 67M 9/2 A WARD R R R S I R I 1.5 3 URINE
17 34M 11/23 A ICU R R R R R R R 2 4 RESP
18 71F 10/26 A ICU R R R R I R I 0.5 2 BLOOD
19 62M 12/6 D ICU R R R R R R R 0.5 6 RESP
20 87F 11/5 F WARD R R R R R R R 0.5 8 BLOOD
21 78M 11/30 E WARD R R R R R R R 2 2 BLOOD
22 65F 9/20 E ICU R R R R S R R 0.75 2 BLOOD
23 43M 8/18 A ICU R R R R S R I 32 4 RESP
24 76M 8/10 E ICU R R R R R R I 0.5 2 BLOOD
25 20M 9/21 A ICU R R I R I R I 2 2 RESP
26 65F 11/9 C ICU R R R R R R I 2 3 RESP
27 71M 9/6 D WARD S I I S S R R 2 URINE
28 45F 9/16 C ICU S S R R S R R 2 RESP
29 50M 3/11 A ICU R R R R R R R 0.5 3 URINE
30 61F 8/26 D ICU R R R R R R R 1.5 2 BLOOD
31 78M 11/10 A WARD S R I R S R R 0.5 2 URINE
Study isolates (plus WC-31, which was isolated from a patient on Hospital Day 1 after transfer from an outside hospital). Legend WC=Weill Cornell; PT=Patient age
and gender; Date: All dates are from 2008; Floor: Each letter represents a different hospital floor; Antimicrobial susceptibility to the various agents was determined
following CLSI guidelines, or the Mean Inhibitory Concentration is reported directly for polymyxin B and tigecycline (mg/mL): A/S: ampicillin-sulbactam, Carb: imipenem
or meropenem; Cef: cefepime; Gent; gentamicin; Amik: amikacin; S/T: sulfamethoxazole-trimethoprim; Levo: levofloxacin; PM: polymyxin B; Tig: tigecycline; Source:
Resp=respiratory. Susceptibility interpretation based on 2008 CLSI cutoff points.
doi:10.1371/journal.pone.0028566.t001
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confirming that this sequence was integron-associated in the study
isolates.
Metabolome Analysis
Metabolic characteristics of both prevalent strain and sporadic
isolates were compared by global metabolomic analysis and
targeted analysis of individual metabolites. Biological replicates of
three prevalent strain isolates (WC-9, WC-11, and WC-18) and 3
sporadic isolates (WC 1, WC-5, and WC-6) were selected and
cultured using glucose as the sole carbon source. Acinetobacter
species are known to metabolize glucose through the Entner-
Doudoroff pathway [16]. The prevalent strain isolates and
sporadic isolates did not differ in metabolites of glucose oxidation
or the Entner-Doudoroff pathway (Figure 3). Finally, we
compared the global metabolome profiles of prevalent strain
isolates and sporadic isolates using Principle Components Analysis
and Hierarchical Clustering Analysis. No significant differences in
the global metabolite profiles of prevalent strain isolates and
sporadic isolates were noted (Figure 3).
Discussion
A. baumannii is now endemic throughout NYC [4]. A limited
number of circulating A. baumannii strains, some from multiple
institutions and other from single sites, have been noted in
previous studies [17–20]. The findings from our study, add to
existing knowledge by showing the geographically wide distribu-
tion of a prevalent strain within one hospital during a period when
no hospital-wide outbreak was suspected. The prevalent strain is a
member of the expanding Worldwide Clone II, formerly known as
European Clone II [15]. Persistence in hospital environments over
prolonged periods appears to be a characteristic of successful A.
baumannii strains [21,22].
The prevalent A. baumannii strain contained a unique Class I
integron sequence. This sequence was also amplified from two
sporadic isolates, suggesting horizontal transfer. Integrons have
been associated with prevalent A. baumannii strains [23], increased
resistance to antibiotics [24], and persistence in hospital
environments [25]. The significance of the partial glucose
sorbosone dehydrogenase gene sequence encoded in the prevalent
integron remains to be elucidated.
It is unclear why some isolates of A. baumannii become epidemic
or endemic, and others remain sporadic. The virulence and
persistence mechanisms of A. baumannii are only beginning to
become understood [26], though significant genomic differences in
A. baumannii isolates that are associated with human, environmen-
tal, or lice host environments have been noted [27]. Epidemic A.
baumannii are able to survive on dry surfaces for prolonged periods
in hospital environments, but do not persist longer than sporadic
A. baumannii [28]. Antibiotic resistance itself is associated with
increased persistence of some A. baumannii strains compared with
more susceptible strains [29], though the relative contribution of
antibiotic resistance and other unspecified virulence factors
remains unknown. We found no significant metabolic differences
between a limited number of tested sporadic isolates and prevalent
strain isolates. While varying environmental conditions may lead
to differences in isolates [30], our results are consistent with a
primary role for antibiotic resistance itself as a marker for A.
baumannii strains with increased potential to persist in hospitals.
Furthermore, in contrast to previous metabolomic analysis of
methicillin-susceptible and -resistant Staphylococcus aureus, as well as
vancomycin-susceptible and -resistant Enterococcus faecium, the
metabolic profiles of the isolates did not segregate by antibiotic
resistance type [12]. This raises the question of whether antibiotic
resistance in A. baumannii requires less metabolomic adaptation (or
‘‘cost’’) compared with these gram-positive organisms. Metabo-
lomic characteristics of A. baumannii have been investigated [31],
but strain to stain metabolomic variability had not been described
to our knowledge. Further study is needed to clarify the metabolic,
proteomic, and genomic differences associated with prevalent and
sporadic MDR A. baumannii.
Figure 1. Rep-PCR Analysis of Study Isolates. Isolates with more than 90% similarity were considered related. Study isolates (WC 1–30) are
shown, plus one isolate (WC-31) isolated on hospital day 1 after transfer from an outside hospital. Results show the majority of the study isolates are
closely related.
doi:10.1371/journal.pone.0028566.g001
Figure 2. Integron Content in Select Study Isolates. Integron PCR gene products of WC 13–24 are shown. The block arrow marks the 550 base
pair PCR product of the prevalent strain A. baumannii. The water control is labeled ‘‘neg.’’ The cartoon shows the layout of a typical Class I integron.
The PCR primers are presented by CS-F and CS-R.
doi:10.1371/journal.pone.0028566.g002
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convenience sample of isolates selected to represent hospital-wide
locations, which raises the potential of selection bias. Though
Rep-PCR was not done on the available but excluded isolates,
antibiogram and integron analysis suggest most excluded isolates
belonged to the prevalent strain (data not shown). Only a subset
of the total A. baumannii isolates from the hospital were collected
over the study period, which may introduce additional bias if the
collected isolates differed in any way from the hospital wide
isolates. However, the antibiotic susceptibility profile of the study
isolates was similar to that of isolates from both ICU and non-
ICU nursing units, suggesting that study isolates were represen-
tative of the hospital-wide A. baumannii strains. Our study period
was only nine months and, thus, it is possible that we detected an
unrecognized outbreak, rather than an endemic period, although
the incidence and prevalence of A. baumannii had been stable for
three years at the time of the study (data not shown). It is also
possible that a longer sampling period would have uncovered
additional prevalent strains of A. baumannii, such as those detected
elsewhere in NYC [18]. Ongoing molecular epidemiologic
surveillance of cultured isolates may further clarify the long term
dynamics of the prevalent endemic A. baumannii strain within the
hospital. Finally, isolates closely related by Rep-PCR may evolve
clinically important differences, such as the differences in
antimicrobial susceptibility testing results seen within the
prevalent strain. Unrelated isolates may exchange genetic
information and potentially share traits, highlighted by the
finding of the prevalent strain integron in two of the sporadic
isolates.
This study characterized the A. baumannii isolates from a NYC
hospital. A previously unsuspected hospital-wide prevalent strain
of multidrug-resistant A. baumannii was uncovered. The prevalent
strain contained a novel integron cassette, though the functional
significance of this finding requires further study. Metabolomic
analysis did not segregate the prevalent strain from sporadic
isolates. Identification of environmental, patient, and bacteria-
specific features associated with the development of persistent A.
baumannii strains will aid efforts to combat this emerging
pathogen.
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